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complete and probably more reliable evalu-
ation of treatment response. Our challenge 
is to understand how to best use CT based 
structural information and functional PET 
information to assess tumor response. We 
have learnt that FDG-PET significantly 
improves staging and restaging of most 
cancers, but we still do not know how 
to best define tumor response based on 
FDG uptake, or how to best measure FDG 
uptake. It is not fully understood how and 
when to best use the FDG-PET for response 
assessment and tumor surveillance. Most 
importantly however our biggest challenge 
is to improve the reproducibility of the 
functional information offered by molecu-
lar imaging so that we can best relate this 
information to established disease outcome 
measures through well designed image 
based clinical trials.
Frontiers in Cancer Imaging and 
Diagnosis welcomes technical and clinical 
papers that address the challenges and limi-
tations of current techniques, or that pre-
sent new findings and potential use of these 
techniques, with the final goal to optimize 
their use. Studies that compare different 
imaging modalities or that show the com-
plementary role multimodality imaging 
are believed to be important to address the 
challenges on how to best utilize the current 
imaging modalities.
The world of cancer imaging is blessed 
by a vibrant community of scientists that 
work to create contrast agents and trac-
ers for different aspects of cancer biology: 
DNA synthesis and cellular proliferation 
(Vesselle et al., 2002), tumor hypoxia 
(Dubois et al., 2004), angiogenesis and 
apoptosis (Beer and Schwaiger, 2008; 
Belhocine, 2008), glucose metabolism to 
cite only some. Many of these new agents 
have already been tested in humans and 
in clinical trials, many are being evalu-
ated in animal imaging trials. Frontiers 
in Cancer Imaging and Diagnosis recog-
nizes the challenges that are associated 
with studies that evaluate the feasibility 
of new imaging modalities, and with the 
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In the last two decades, the field of cancer 
imaging has witnessed tremendous evo-
lution which has impacted virtually every 
aspect of research and clinical manage-
ment of cancer. This evolution has been the 
result of innovations in two main aspects: 
1. Instrumentation and 2. Development 
of new contrast agents and radiolabeled 
tracers. Among the most significant inno-
vations in instrumentation, the introduc-
tion of “hybrid” scanners such as PET/CT 
(Townsend et al., 2004) has provided new 
tools for the characterization, staging, and 
restaging of many types of cancer. New 
more sensitive and faster scanners, new 
hybrid combinations such as PET/MRI are 
already available, and new contrast agents 
and radiolabeled tracers for MRI, ultra-
sound, PET/SPECT, and optical imaging 
are being developed. The evolution toward 
more sensitive “hybrid” scanners and of 
new imaging agents has led to the growth 
of the field of Molecular Imaging which, as 
defined by the Molecular Imaging Center 
of the Society of Nuclear Medicine is “The 
visualization, characterization, and meas-
urement of biological processes at the 
molecular and cellular levels in humans 
and other living systems.” It is particularly 
important that progress in cancer imaging 
continues, to parallel the advancements in 
the understanding of the molecular and 
cellular processes of cancer transforma-
tion. Translational research on cancer 
biology can benefit from the contribution 
of molecular imaging to produce valuable 
diagnostic and prognostic in vivo biomark-
ers to support and improve the discovery, 
development, and testing of new thera-
peutic tools, alone or in combination with 
existing treatment modalities. The final 
product of this process would be that for 
each patient there is a personalized biologi-
cal characterization of cancer leading to 
individualized treatment and assessment 
of tumor response. Existing clinical trials 
have already included molecular imaging 
and specifically PET/CT in the algorithm 
to assess response to treatment earlier and 
more accurately. For example, CALGB 
50804 and 50604 phase II clinical trials for 
non-bulky and bulky Hodgkin lymphoma 
use PET/CT to provide an early assessment 
of treatment response after two cycles of 
chemotherapy in order to guide response-
adapted individualized patient treatment. 
Patients with a negative PET/CT scan are 
classified as early responders and con-
tinue on the same chemotherapy regimen, 
whereas non-responders are switched to 
a different chemotherapy with or without 
radiation therapy. In solid tumors, the 
MUNICON phase II trial (Lordick et al., 
2007) uses PET/CT imaging for an early 
assessment of response after two cycles 
of neoadjuvant chemotherapy in patients 
with esophageal cancer. Responders receive 
the full course of chemotherapy whereas 
non-responders will go directly to surgery 
without additional cycles of neoadjuvant 
chemotherapy.
As cancer imaging is moving toward 
the goal to provide reliable and sensitive 
markers for tumor diagnosis and assess-
ment of response to treatment, the limita-
tions and challenges of this field become 
however more apparent and new questions 
are raised, not only for the new imaging 
techniques and tracers under development, 
but also for the more established imaging 
modalities. As progress is being made, we 
need to turn back to the techniques and 
guidelines in current use and ask ourselves 
if we can do better. Are RECIST (Therasse 
et al., 2000; Eisenhauer et al., 2009) crite-
ria for response assessment in solid tumors 
adequate, or should we use a volumetric 
assessment of tumor size? Do we need 3D 
measurements of tumor volumes and if so, 
do we have adequate software for a rou-
tine 3D measurement of tumor volumes 
in standard clinical care or in clinical tri-
als? As we learn more on tumor biology 
through FDG-PET imaging, we realize the 
limitations of size criteria for response 
assessment (for review see Weber, 2009), 
and understand that a combined structural 
and functional assessment offers a more Frontiers in Oncology | Cancer Imaging and Diagnosis    July 2011  | Volume 1  |  Article 15  |  2
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imaging techniques, all the way to studies 
that explore the role of molecular imaging 
during patient treatment.
There is no question that the ever 
evolving field of Cancer Imaging remains 
a central portion in the research and clini-
cal management of cancer, and there is no 
question that although many challenges 
remain ahead, this field will contribute 
to continued improvement in the detec-
tion of the disease and to more effective 
treatments.
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use of these new agents to explore the 
effect of cancer treatment on different 
aspects of tumor biology, and welcomes 
publications in this field. These studies 
will eventually lead to a more individu-
alized assessment of tumor biology and 
personalized treatments.
Progress in cancer imaging can also 
guide toward a more personalized and 
potentially more effective use of image 
guided interventions. As a number of 
image guided interventions are available 
(focused radiation treatment, emboliza-
tion, chemoembolization, radiofrequency 
ablation, radiochemoembolization etc.), 
we realize that some of these interven-
tions are more successful for some types/
subtypes of tumors or biological cancer 
conditions, and less successful in oth-
ers. It is conceivable for example, that in 
conditions of hypoxia, tumors may be 
more resistant to treatment (Eschmann 
et al., 2005), and it is conceivable that for 
instance imaging of tumor hypoxia could 
direct the type and timing of local interven-
tions in coordination with systemic treat-
ments. The challenges ahead are not only 
in the production of the imaging agents 
and choice of best imaging modality, but 
also in the design and implementation of 
appropriate translational trials to apply the 
information obtained from imaging to the 
type of treatment and patient outcomes. 
Frontiers in Cancer Imaging and Diagnosis 
welcomes publication of studies from the 
initial phases of implementation of new 